Blockchain Registration Transaction Record

Oncotelic's Breast Cancer Therapy Accepted for 2025 Symposium

Oncotelic Therapeutics announces Sapu Nano's Deciparticle everolimus accepted for 2025 San Antonio Breast Cancer Symposium, advancing novel cancer treatment for HR+/HER2- metastatic breast cancer.

This development represents a significant advancement in cancer treatment that could directly impact millions of patients worldwide. Breast cancer remains one of the most common cancers globally, with HR⁺/HER2⁻ metastatic breast cancer representing a particularly challenging subtype where new treatment options are desperately needed. The improved bioavailability and reduced toxicity profile of Sapu003 could mean fewer side effects and better quality of life for patients undergoing treatment. Enhanced tumor penetration capabilities suggest potentially higher efficacy rates, which could translate to improved survival outcomes. For patients with renal cell carcinoma and neuroendocrine tumors - both difficult-to-treat cancers - this innovation offers new hope where existing treatments often fall short. The presentation at a major international symposium indicates peer recognition of the therapy's potential, moving it closer to clinical application where it could address critical gaps in current cancer care.